RAD Radiopharm Theranostics Ltd
- 0.033
- -0.002-5.71%
Radiopharm Theranostics Ltd News
Radiopharm Theranostics to Be Featured in Healthcare Events Hosted by B. Riley Securities
Radiopharm Theranostics (ASX:RAD) said it will be featured in a range of healthcare events being hosted by B. Riley Securities in May. The events will be hosted in New York and virtually. They will co
Radiopharm Theranostics Advances Cancer Treatment With RAD 301 and RAD 302 Developments
Radiopharm Theranostics (ASX: RAD) has welcomed the release of new data identifying a promising pathway for its innovative RAD 301 and RAD 302 oncology developments.
Radiopharm Theranostics to Present Multiple Data Releases for RAD 301 at European Molecular Imaging Meeting
Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF) will present multiple data sets on its 68Ga-Trivehexin (RAD 301) technology during the European Molecular Imaging Meeting (EMIM) from March 12-15, 2024, in Porto, Portugal.
Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study
Radiopharm Theranostics (ASX:RAD) dosed the first patient in a Phase 1 clinical trial investigating the safety and imaging profile of the radiopharmaceutical drug RAD 301, the radiotherapeutics firm s
Radiopharm Theranostics Doses First Patient in RAD 301 Pancreatic Cancer Study
Biotechnology company Radiopharm Theranostics (ASX: RAD) has dosed the first patient in a Phase 1 study assessing the safety, dosimetry and imaging characteristics of the RAD 301 isotope in the treatment of advanced pancreatic cancer.
Radiopharm Theranostics Set to Revolutionise Prostate Cancer Treatment With Terbium-161
A recent medical publication into prostate cancer has validated the development by clinical-stage biotech Radiopharm Theranostics (ASX: RAD) of its first-in-class Terbium-161 (Tb-161).
Radiopharm Theranostics Has Terbium-161 Radiotherapeutics Validated by Pilot Study in Prostate Cancer
Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF) has highlighted a head-to-head pilot study in prostate cancer which validates its development of first-in-class Terbium-161 radiotherapeutics.
Radiopharm Theranostics Boosts Clinical Trials Pipeline With $1.9m R&D Advance
Radiopharm Theranostics (ASX: RAD) continues to build up its bank balance with the receipt of $1.9 million as an advance on its anticipated FY24 research and development (R&D) tax incentive (RDTI).
Radiopharm Theranostics Secures A$1.9 Million Advance on R&D Tax Incentive
Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF) has exercised a funding facility with Radium Capital, receiving A$1.9 million in anticipation of a research and development (R&D) tax incentive from the Australian Federal Government.
Radiopharm Secures Investment From US-based Lind Partners; Shares Decline 6%
Radiopharm Theranostics (ASX:RAD) said Tuesday that it secured investment from New York-based institutional investor Lind Partners' Lind Global Fund II. Under the share subscription agreement, Radioph
Radiopharm Theranostics Secures up to A$12.5 Million to Support Clinical Trial Pipeline
Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF) has secured an investment of up to A$12.5 million from US institutional investor Lind Partners.
Radiopharm Theranostics Confirms DUNP19 Can Halt Tumour Progression and Prolong Cancer Survival
A study by biotechnology company Radiopharm Theranostics (ASX: RAD) has shown that non-invasive clinical imaging and targeted radioimmunotherapy with lead candidate DUNP19 (RAD 502) is able to halt tumour progression and prolong survival in various cancer models.
Radiopharm Theranostics' Novel Monoclonal Antibody Shows Promise in Cancer Treatment
Radiopharm Theranostics Ltd (ASX:RAD, OTC:RDPTF) has unveiled promising results from a study on its innovative treatment, DUNP19 (RAD 502), led by Dr David Ulmert and his team at the University of California, Los Angeles.
Radiopharm Theranostics Expands Pioneering Lung Cancer Treatment Study to Perth
Radiopharm Theranostics (ASX: RAD) has expanded its phase 1 study into a novel radiotherapeutic treatment for non-small-cell lung cancer (NSCLC).
Radiopharm Theranostics Raises AU$1.7 Million Via Shortfall Placement
Radiopharm Theranostics (ASX:RAD) raised AU$1.7 million from the shortfall placement of 24,025,716 shares at AU$0.07 apiece. Shares under the placement will settle Jan. 30 and will be issued Jan. 31,
Radiopharm Increases Focus on New Lung Cancer Treatment
Radiopharm Theranostics is poised to open a second front for conducting human trials of its promising RAD 204 treatment for advanced non-small cell lung cancer (NSCLC) having received the green light from Perth’s Hollywood Private Hospital Human Research Ethics Committee.
Radiopharm Theranostics Secures Ethics Approval for Second Lung Cancer Trial Site
Radiopharm Theranostics (ASX:RAD) secured ethics approval for a second trial site for its upcoming phase one trial investigating Lu-RAD 204 therapy as a treatment for patients with non-small cell lung
Radiopharm Theranostics to Start Phase One Lung Cancer Therapy Trial
Radiopharm Theranostics (ASX:RAD) is set to start a phase one trial investigating the safety and tolerability of the RAD 204 therapy in patients with metastatic non-small cell lung cancer by Jan. 4, 2
Radiopharm Theranostics Raises AU$2.1 Million Via Entitlement Offer
Radiopharm Theranostics (ASX:RAD) completed a 1-for-2.35 entitlement offer of 30,197,244 shares at AU$0.07 each to raise about AU$2.1 million. The shares under the entitlement offer were issued Dec. 8
Radiopharm Theranostics Secures AU$5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 4%
Radiopharm Theranostics (ASX:RAD) secured AU$4.8 million tax rebate for the fiscal year ended June 30 from the Australian government's research and development tax incentive scheme. Proceeds will be u
Analysis
Price Target
No Data
